Investigating the impact of fluid removal speed on heart strain during dialysis
The Effect of Hemodialysis on proBNP
This study tests if changing how quickly fluid is removed during dialysis can help reduce heart strain in adults who have gained weight between treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Umeå University Academic / other |
| Locations | 1 site (Umeå) |
| Trial ID | NCT06153888 on ClinicalTrials.gov |
What this trial studies
This study examines how the rate of fluid removal during chronic hemodialysis affects the release of cardiac markers, specifically NT-proBNP, which is associated with heart strain. By analyzing patients who experience significant inter-dialytic weight gain, the research aims to determine if adjusting the ultrafiltration rate could improve cardiovascular outcomes. The findings may lead to updated guidelines for dialysis prescriptions to better manage fluid overload and reduce cardiac risks in patients. The study involves adult patients undergoing hemodialysis and focuses on their physiological responses during treatment.
Who should consider this trial
Good fit: Ideal candidates are adult hemodialysis patients with significant inter-dialytic weight gain of 2.5% or more of their target weight.
Not a fit: Patients with active systemic inflammatory conditions or uncontrolled hyperphosphatemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved dialysis prescriptions that reduce cardiovascular risks for patients with fluid overload.
How similar studies have performed: While there is ongoing research in this area, the specific approach of correlating ultrafiltration rates with cardiac strain markers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult HD patients with an intra-dialytic weight gain (IDWG) ≥2.5% of target weight over the long interval (3 days) prior to inclusion. * Patients need to be able to understand the study information * Patients need to be able to give consent. Exclusion Criteria: * Active systemic inflammatory state such as extensive malignancy or acute septic infection. * Uncontrolled hyperphosphatemia decided by the local routine of the physician (due to somewhat decreased efficacy of the low flux filter to eliminate phosphate)
Where this trial is running
Umeå
- Region Vasterbotten, Norrlands Universitetssjukhus, Dialysen — Umeå, Sweden (Recruiting)
Study contacts
- Principal investigator: Bernd Stegmayr, MD, PhD — Umea University, Umea, Sweden
- Study coordinator: Bernd Stegmayr, MD, PhD
- Email: bernd.stegmayr@umu.se
- Phone: +46706264533
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.